Study Name Clinicaltrials.gov Identifier | Phase | Intervention | Setting | Location |
---|---|---|---|---|
Advanced Disease | ||||
Targeted Agents With Cytotoxic Therapy | ||||
NCT00832637 | II | Erlotinib + gemcitabine + oxaliplatin | Prior systemic therapy allowed | US |
HOG GI06-101 NCT00532441 | II | Erlotinib + docetaxel | Third-line or less | US |
NCT00384800 | II | Thalidomide + tegafur/uracil | No prior chemotherapy | Taiwan |
NCT00519688 | II | Thalidomide + tegafur/uracil | No prior chemotherapy | Taiwan |
NCT00862082 | I/II | Sorafenib + PR104 Sorafenib | First-line | US, Asia |
Anti-VEGF Agents as Monotherapy | ||||
BRISK NCT00858871 | III | Brivanib + placebo Sorafenib + placebo | First-line | International |
NCT00825955 | III | Brivanib + placebo BSC + placebo | Sorafenib failure | International |
NCT00699374 | III | Sunitinib Sorafenib | First-line | International |
NCT00247676 | II | Sunitinib | First-line | France, Korea, Taiwan |
Other Targeted Agents as Monotherapy | ||||
NCT00225290 | III | Thalidomide Placebo | Any line Poor liver reserve | Taiwan |
NCT00033462 | II | Erlotinib | First- or second-line | US |
NCT00077441 | II | Bortezomib | First-line | US, Australia, Korea, HK |
NCT00390195 | I/II | Everolimus (weekly or daily) | Any line | Taiwan |
NCT00920192 | I/II | Foretinib | Any line | Taiwan, HK |
Combination Targeted Therapy | ||||
SEARCH NCT00901901 | III | Sorafenib + erlotinib Sorafenib | First-line | International |
NCT00881751 | II | Erlotinib + bevacizumab Sorafenib | First-line | US |
NCT00365391 | II | Erlotinib + bevacizumab | First- or second-line | US |
TCOGP-1209 NCT00971126 | I/II | Thalidomide + sorafenib | First-line | Taiwan |
NCT00828594 | I/II | Everolimus + sorafenib Placebo + sorafenib | First-line | International |
NCT00791544 | I/II | AVE1642* +/- sorafenib or erlotinib | Any line | France |
Earlier-stage Disease | ||||
STORM NCT00692770 | III | Sorafenib Placebo | Adjuvant (post-resection or -local ablation) | International |
BRISK-TA NCT00908752 | III | Brivanib + TACE Placebo + TACE | BCLC B | International |
NCT00921531 | III | Thalidomide + TACE TACE | BCLC A-B | China |
NCT00728078 | II/III | Thalidomide, low dose | Adjuvant (post-RFA) | China |
START NCT00990860 | II | Sorafenib + TACE | BCLC B | Taiwan |
NCT00855218 | II | Sorafenib + TACE Placebo + TACE | BCLC B | International |
COTSUN NCT00919009 | II | Sorafenib + TACE | TNM III/IVa | Korea |
NCT00576199 | II | Bevacizumab | Pre- and Post-TACE | HK |
JLOG 0901 NCT00933816 | I/II | Sorafenib + fluorouracil/platinum HAI | Not suitable for resection, ablation, TACE | Japan |
NCT00293436 | I/II | Erlotinib + celecoxib | Adjuvant (post-resection, -TACE, or -RFA), high-risk | US |